Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma

University of Michigan Rogel Cancer Center6 enrolled

Overview

Glioblastomas (GBM) demonstrate in vivo genetic and histologic heterogeneity that can be non-invasively identified using imaging phenotypes that identify regionally distinct areas of tumor with genetic alterations that drive tumor resistance pathways. The researchers propose a unique approach to assess initial GBM heterogeneity by performing histological and genomic analysis of biopsies targeted by advanced MRI before treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Glioblastoma

Interventions

Tumor BiopsyOTHER

Stereotactic biopsies will be performed prior to resection.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Suspected newly diagnosed or recurrent supratentorial glioblastoma eligible for surgical biopsy and/or resection * Patients must be 18 years of age or older * Study-specific informed consent approved for this purpose by the IRB of the University of Michigan Exclusion Criteria: * Patients unable to undergo MRI

Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes